PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor MALVERN, Pa. and SAN DIEGO, Feb. 11, 2020 (GLOBE NEWSWIRE) — PhaseBio […]

PhaseBio to be responsible for all development, manufacturing and commercialization MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement […]